IC800 / IACTA Pharma - LARVOL DELTA

IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain (PRNewswire) - "IACTA Pharmaceuticals...today announced they have entered into licensing agreements, with IACTA acquiring global rights to Pharmaleads' Dual Enkephalinase Inhibitors (DENKI®)...Under the terms of these agreements...Pharmaleads and Pharmaleads Greater China will together be eligible to receive up to $100M in total deal value...Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 (acute) and IC805 (chronic) and other DENKI drugs...IACTA expects to start human proof of concept trials in ocular pain in 2021."

Licensing / partnership • New trial • Pain